Background Clostridium difficile infection causes severe complications and frequently recurs. An extended-pulsed fidaxomicin regimen might facilitate sustained clinical cure by prolonging C difficile suppression and supporting gut microbiota recovery. We aimed to compare clinical outcomes of extended-pulsed fidaxomicin with standard vancomycin.
Introduction
Clostridium difficile is the leading cause of infectious health-care-associated diarrhoea in developed countries. 1 C difficile infection is particularly serious in older individuals, in whom it is associated with severe infection and complications, including recurrence and death. [2] [3] [4] Prevention of recurrence of C difficile infection has been identified as a key unmet need. 5 Recurrence is estimated to occur in up to 25% of patients treated with metronidazole or vancomycin, 5, 6 is associated with a substantial health-care burden, 6 and is a particular problem in high-risk individuals. 7 Previous administration of antimicrobials typically results in disruption of the colonic microbiota, preceding C difficile colonisation. 8, 9 Recurrence is thought to be a consequence of delayed recovery of this previously disrupted microbiota during C difficile infection therapy. 8 Although oral vancomycin is the standard of care for severe C difficile infection, 3 this drug has a substantial deleterious effect on the intestinal bacterial microbiota. 10, 11 The narrow-spectrum macrocyclic antibiotic fidaxomicin showed efficacy and tolerability for treatment of C difficile infection when administered as a standard regimen (200 mg orally twice daily for 10 days), and is non-inferior to standard vancomycin (125 mg orally four times daily for 10 days) in achieving initial clinical cure. 12, 13 Fidaxomicin is better able to preserve the gut microbiota than is vancomycin, 10 which might explain the well-documented reduced C difficile infection recurrence (about 15%) and improved sustained clinical cure (about 75%) with fidaxomicin compared with vancomycin (about 27% for C difficile infection recurrence and 64% for sustained clinical cure). 12, 13 Evidence from a validated in-vitro human gut model suggests that an extended-pulsed fidaxomicin regimen, which extends 20 fidaxomicin doses over a longer time period after initial daily dosing, might allow persistence of fidaxomicin at above inhibitory concentrations, thus prolonging suppression of C difficile, and simultaneously facilitating microbiota recovery. 14 Consequently, extended-pulsed fidaxomicin is hypothesised to show equivalent efficacy to vancomycin in resolving C difficile infection. This drug regimen might also have the potential to reduce C difficile infection recurrence beyond that documented for standard fidaxomicin and increase sustained clinical cure.
We aimed to assess clinical outcomes of extended-pulsed fidaxomicin compared with vancomycin, with a primary efficacy endpoint of sustained clinical cure of C difficile infection 30 days after the end of treatment, in a microbiota-sparing strategy.
Methods

Study design and patients
We did a phase 3b/4, randomised, controlled, parallel, superiority, open-label trial at 86 hospitals in 21 European countries. Hospitalised patients were eligible for inclusion if they were aged 60 years and older with clinically confirmed C difficile infection, defined by either more than three unformed bowel movements or at least 200 mL unformed stool (for patients with rectal collection devices) in the 24 h before randomisation, in addition to presence of C difficile toxin A or B in stool within 48 h of randomisation by local laboratory C difficile infection toxin test. Key exclusion criteria included C difficile infection therapy for more than 1 day within the past 48 h and more than two previous C difficile infection episodes within 3 months of enrolment (see appendix for full list of exclusion criteria). Before the first patient was enrolled, there was a country-specific protocol amendment in
Research in context
Evidence before this study Metronidazole and vancomycin have been the mainstays of Clostridium difficile infection treatment for several decades, with vancomycin efficacy superior to that of metronidazole. We searched PubMed for articles published in any language up to March 6, 2017, using the terms "Clostridium difficile infection" and "recurrence". We identified several studies and reviews that reported recurrence rates of up to 25%. We noted advanced age as a risk factor for C difficile infection recurrence and adverse outcomes following treatment. In fidaxomicin phase 3 registration studies, more than half of patients were at least 60 years of age. These studies were the first to show that fidaxomicin was non-inferior to vancomycin for clinical cure, but also associated with a reduction in C difficile infection recurrence compared with vancomycin. Adjunctive therapy with the monoclonal antibody bezlotoxumab plus standard of care showed a reduction in C difficile infection recurrence compared with placebo at 12 weeks post-infusion. In-vitro gut model evidence supports the potential benefits of an extended-pulsed fidaxomicin treatment regimen with respect to rapid clearance of C difficile while simultaneously supporting recovery of microbiota that are important for subsequent colonisation resistance. Evidence for alternative fidaxomicin dosing strategies, including chaser and pulsed regimens for recurrent C difficile infection, is limited to small case series, as is evidence for pulsed regimens of vancomycin.
Added value of this study
This phase 3b/4 study shows superiority of extended-pulsed fidaxomicin over standard vancomycin in achieving sustained clinical cure of C difficile infection in an older patient population. Addition of a pulsed fidaxomicin dosing period did not adversely affect rates of initial clinical cure and resulted in reduced C difficile infection recurrence rates compared with vancomycin. The recurrence rate with extended-pulsed fidaxomicin treatment, monitored over 90 days, is the lowest reported to our knowledge in a randomised controlled trial of C difficile infection antibiotic treatment. Furthermore, disease-free survival was higher in extended-pulsed fidaxomicin patients compared with patients receiving vancomycin. Addition of novel exploratory microbiology endpoints also allows interpretation of microbiome diversity, for the first time to our knowledge, in a C difficile infection-targeting antibiotic randomised controlled trial. The shift in bacterial diversity up to day 55 was greater in extended-pulsed fidaxomicin patients compared with vancomycin patients, which supports the hypothesis that extended-pulsed fidaxomicin facilitates recovery of the microbiota during treatment. Sustained efficacy with the extended-pulsed fidaxomicin regimen was achieved with no increase in treatment costs and no detriment to safety compared with standard-regimen vancomycin and fidaxomicin.
Implications of all the available evidence
Prevention of recurrence of C difficile infection is recognised as a key unmet clinical need, particularly in high-risk populations, such as older patients. The EXTEND study addresses sustained cure as a primary measure of treatment success in a high-risk patient population, with recurrence monitored up to day 90. To our knowledge, this study provides the first clinical evidence for extended-pulsed fidaxomicin as an efficacious and well-tolerated treatment option for C difficile infection. Available in-vitro and clinical evidence suggests that the sparing effect of fidaxomicin on the gut microbiota might contribute to observed treatment outcomes.
See Online for appendix
Germany at the request of the local ethics committee because of concerns over potential fidaxomicin overabsorption in patients with inflammatory bowel disease. Thus, patients with inflammatory bowel disease were also excluded from the study. Institutional review boards at each site approved the study protocol and amendments. Patients provided written informed consent.
Randomisation and masking
Patients were centrally randomly assigned (1:1), using an interactive web response system, to receive extendedpulsed fidaxomicin or vancomycin. Random isation was stratified by baseline C difficile infection severity (severe or non-severe; severe defined as leucocyte count >15 × 10⁹ cells per L or rise in serum creatinine [>50% above a patient's normal level] or albumin <30 g/L), presence or absence of cancer (defined as diagnosis of cancer within 6 months of the study or ongoing therapy for cancer treatment), age (≥75 years or <75 years), or number of previous C difficile infection occurrences (zero, one, or two) in the 3 months before study entry, with a block size of four, which was agreed before entry. Patients were recruited by the study investigators at sites in Europe, Russia, and Turkey.
Patients could participate in pharmacokinetic and microbiome (16S rRNA sequencing) substudies to analyse the concentration of fidaxomicin in blood (plasma), and the microbiome profile in stool samples.
Procedures
Presence of C difficile infection was locally confirmed at the screening visit. Patients received commercially available oral fidaxomicin 200 mg film-coated tablets (Astellas Pharma Europe, Leiden, Netherlands) twice daily on days 1-5, then once daily on alternate days on days 7-25 (extended-pulsed fidaxomicin), or commercially available oral vancomycin 125 mg capsules (Xellia Pharmaceuticals, Copenhagen, Denmark), four times daily on days 1-10.
At the test of cure visit on day 12 for vancomycin and day 12 or day 27 for extended-pulsed fidaxomicin, C difficile infection assessments, severity score, and clinical response were assessed. Clinical response was based on European Society of Clinical Microbiology and Infectious Diseases criteria. 3 Sustained clinical cure, defined as clinical response at test of cure and no C difficile infection recurrence, was determined on days 40, 55, and 90 (end of follow-up). All other cases were deemed treatment failures for sustained clinical cure.
For patients with clinical response at test of cure, recurrence of C difficile infection was defined as return of diarrhoea after test of cure to an extent (according to the frequency of unformed bowel movements) that was greater than the frequency recorded on day 10 for the vancomycin arm or day 25 for the extended-pulsed fidaxomicin arm, confirmed by a local C difficile infection test positive for toxin A or B and requiring further therapy. Recurrence was assessed up to day 90.
Stool samples were collected for all patients at screening (day 0) and, in the case of treatment failure or C difficile infection recurrence, stool samples underwent microbiological testing at a central laboratory (LGC, Fordham, UK). Samples were tested for the presence of C difficile toxin A or B using a qualitative ELISA, and bacterial, parasitic, or viral enteric pathogens, including C difficile, according to established methods (PCR-based multiplex test; BioFire FilmArray Gastrointestinal Panel, Biomérieux, Marcy-l'Étoile, France).
Pharmacokinetic assessments were done on days 5, 12, and 27. Stool samples for overall microbial diversity (microbiota substudy) analysis were collected on days 0, 5, 12, 27, 40, and 55, and at unscheduled visits for treatment failure or C difficile infection recurrence, and were tested at LGC Genomics, Berlin, Germany. Total bacterial DNA was extracted and the 16S rRNA gene sequenced (Illumina MiSeq V3, Illumina, San Diego, CA, USA) to measure changes in bacterial diversity following treatment with extended-pulsed fidaxomicin or vancomycin (appendix). The Shannon index of α diversity was calculated using Qiime version 1.9.0.
Patients were followed up at least every 2 weeks to check for C difficile infection recurrence, adverse events, and concomitant medication. If the patient was discharged from hospital, this follow-up might have been done by telephone. Information was collected if patients died, were readmitted to hospital, or if they received treatment or diagnostic procedures as either an inpatient or outpatient (resource utilisation).
Outcomes
The primary efficacy endpoint was sustained clinical cure of C difficile infection at 30 days after end of treatment (day 40 for vancomycin and day 55 for extended-pulsed fidaxomicin). Secondary endpoints were sustained clinical cure of C difficile infection at days 40, 55, and 90 for both treatment groups; clinical response of C difficile infection at day 12 and at 2 days after end of treatment (day 12 or day 27 for both vancomycin and extended-pulsed fidaxomicin); rate of relapse at day 90 as determined by whole genome sequencing of C difficile isolates from patients who had documented recurrence after test of cure; time to resolution of diarrhoea from the start of treatment, sustained to test of cure (ie, time of the last unformed bowel movement the day before the first of two consecutive days of ≤3 unformed bowel movements, >50% reduction in number of stools, or >75% reduction in liquid stool volume); recurrence of C difficile infection at days 40, 55, and 90; time to C difficile infection recurrence after end of treatment (for patients with clinical response); disease-free survival after day 10 (for patients with clinical response); incidence of mortality and severity of adverse events at day 90; healthrelated quality of life up to day 55; and readmission and For Qiime software see http://qiime.org/ length of hospital stay at day 90. At the time of writing, data were not available on health-related quality of life, readmission, or length of stay, and these data will be reported separately. Exploratory endpoints included the number and volume of unformed bowel movements per day, and microbial diversity in stool samples. Safety was assessed from the first day of study treatment (day 1) to the end of study visit (day 90). Adverse events were recorded at each study visit and assessed by a local investigator for severity and relationship to study drug. Adverse events of mild intensity were defined as those that did not disrupt normal daily activities.
Statistical analysis
To detect a difference between extended-pulsed fidaxomicin and vancomycin in relation to the primary endpoint, a maximum sample size of 346 patients (173 per arm) provided approximately 90% power at a two-sided overall significance level of 0·05. Assumptions were based on sustained clinical cure rates of 85% for extended-pulsed fidaxomicin and 70% for vancomycin (corresponding to an odds ratio [OR] of 2·43), 12, 13 accounting for an interim analysis conducted after about 55% of patients with confirmed C difficile infection had completed the primary endpoint assessment. We planned to recruit an additional 18 patients to allow for incorrect inclusion of patients without positive C difficile culture confirmed at baseline.
Descriptive statistics are provided for continuous and categorical variables. All null hypotheses assumed no treatment difference and all alternative hypotheses were two-sided. Sustained clinical cure at 30 days after end of treatment was summarised by treatment group and the difference between the two treatment arms was compared across strata using the Cochran-Mantel-Haenszel test, adjusting for baseline stratification factors. Similar analyses were done for the secondary endpoints of sustained clinical cure at days 40, 55, and 90, clinical response (at day 12 and at 2 days after the end of treatment), and recurrence of C difficile infection (at days 40, 55, and 90). The significance level for comparison of the primary endpoint was 0·0425 for the final analysis. Additionally, multivariate analysis (logistic regression), which included treatment arm and baseline stratification factors as covariates, was done. If the primary endpoint differed significantly between treatment arms, then adjusted p values were obtained using the Hochberg procedure for endpoints of sustained clinical cure at days 40, 55, and 90, clinical response at day 12, and rate of relapse on day 90. For the endpoints time to C difficile infection recurrence after end of treatment, disease-free survival after day 10, and time to resolution of diarrhoea, the Kaplan-Meier method was used for the analyses and the stratified Wilcoxon-Gehan test used to compare survival (Kaplan-Meier) estimates. Time to resolution of diarrhoea was analysed using the Cox proportional hazards model, adjusting for treatment arm and baseline stratification factors. Differences in bacterial diversity were analysed using paired t tests.
Two study populations, the modified full analysis set and per-protocol set, were analysed for primary and secondary endpoints. The modified full analysis set comprised all randomised patients who met inclusion criteria and received at least one dose of study medication, and was the primary analysis set for efficacy. The perprotocol set comprised all patients in the modified full analysis set who had no major protocol deviations before assessment of the primary clinical endpoint and received at least 70% of the study treatment (appendix). The safety analysis set included all randomised patients who received at least one dose of study medication.
All analyses were done using SAS version 9.3. EXTEND is registered with ClinicalTrials.gov, number NCT02254967. An independent data monitoring committee continually reviewed drug safety.
Role of the funding source
The study sponsor was involved in all stages of the study, including manuscript development. The corresponding author had full access to all the data in the study and had Data are n (%) unless otherwise specified. *Not all study sites were permitted to report the race of patients, and in these cases this information was reported as missing. †Provided by interactive web response system at randomisation; type of cancer recorded only for medical history and not for analysis. ‡In the 90 days before the study. §A nursing home provides supportive care, whereas a long-term care facility provides rehabilitative care with a greater number of clinical personnel and facilities. final responsibility for the decision to submit for publication.
Results
Between Nov 6, 2014, and May 5, 2016, 403 patients were screened for inclusion in the study. 39 patients were excluded due to screening failure and thus 364 patients were randomly assigned to receive extended-pulsed fidaxomicin or vancomycin (figure 1). 362 patients received at least one dose of study medication (181 received extended-pulsed fidaxomicin and 181 received vancomycin) and were included in the safety analysis (figure 1). Two patients randomised to extendedpulsed fidaxomicin did not have clinically confirmed C difficile and did not receive treatment.
Two patients in the vancomycin group and four in the extended-pulsed fidaxomicin group did not have confirmed C difficile infection, so were excluded from the modified full analysis set. Both treatment groups were similar regarding baseline characteristics, including age, C difficile infection severity, number of previous C difficile infection occurrences, and number of unformed bowel movements in the 24 h before randomisation (table 1) .
For the primary efficacy endpoint, 124 (70%) of 177 patients in the extended-pulsed fidaxomicin group had sustained clinical cure at 30 days after end of treatment compared with 106 (59%) of 179 patients who received vancomycin (OR 1·62 [95% CI 1·04 -2·54]; p=0·030, Cochran-Mantel-Haenszel test [primary analysis] and p=0·035, multivariate analysis; figure 2, table 2).
Results for the primary endpoint in the per-protocol set were similar to those in the modified full analysis set, with sustained clinical cure at 30 days after end of treatment higher in patients who received extended-pulsed fidaxomicin compared with those who received vancomycin (p=0·001; table 3). In the modified full analysis set only, multivariate analysis for sustained clinical cure at 30 days after end of treatment, adjusted for baseline stratification factors, showed that patients with severe C difficile infection were less likely to achieve sustained clinical cure than were patients with nonsevere C difficile infection (table 2) . Extended-pulsed fidaxomicin was associated with an increased rate of sustained clinical cure compared with vancomycin at 30 days after end of treatment in patients with PCR ribotype 027 infections (table 2). More patients in the extended-pulsed fidaxomicin arm than in the vancomycin arm achieved the secondary efficacy endpoint of sustained clinical cure at days 40, 55, and 90 in the modified full analysis set (table 2, figure 2) and perprotocol set (table 3) .
At day 12 and day 27 (2 days after end of treatment), the clinical response to treatment did not differ between the extended-pulsed fidaxomicin and vancomycin study arms for the modified full analysis set (table 2, figure 2 ) and the per-protocol set (table 3) .
For patients who had clinical response to treatment at test of cure visit (day 12 for vancomycin and day 27 for extended-pulsed fidaxomicin), fewer patients in the extended-pulsed fidaxomicin than in the vancomycin arm had recurrence of C difficile infection at all three timepoints (day 40, day 55, and day 90; tables 2, 3; figure 2 ). At 30 days after end of treatment (day 55 for extended-pulsed fidaxomicin and day 40 for vancomycin), recurrence had occurred in seven (4%) patients receiving extended-pulsed fidaxomicin and 30 (17%) patients receiving vancomycin. Time to C difficile infection recurrence was longer after the end of treatment with extended-pulsed fidaxomicin than with vancomycin (p<0·0001; appendix).
The median time from start of treatment to resolution of diarrhoea appeared to favour vancomycin (censored at day 10, end of treatment) rather than extended-pulsed fidaxomicin (censored at day 25, end of treatment), although groups did not differ in the modified full analysis set (table 2) or the per-protocol set (table 3) .
Most patients (127 of 137 extended-pulsed fidaxomicin patients and 114 of 147 vancomycin patients, of those who responded at test of cure) did not show symptoms of diarrhoea after day 10 and remained in the analysis until they discontinued or completed the study, after which they were censored. The time taken after day 10 for the first 5% of patients in the extended-pulsed fidaxomicin arm to have C difficile infection recurrence was 47 days (95% CI 23·0-not reached), compared with Extended-pulsed fidaxomicin (n=177)
Percentage of patients -2% p=0·721 16% p=0·0013 11% p=0·030 20 10 9 days (95% CI 4·0-10·0) in the vancomycin arm. This overall difference in disease-free survival was significant (p=0·003; appendix). A hazard ratio of 0·26 (95% CI 0·12-0·50) was determined from a Cox proportional hazards model, adjusted for baseline stratification factors. This result suggests that the hazard of C difficile infection recurrence at any given time after day 10 for a vancomycin-treated patient was approximately 3·8-times that of an extended-pulsed fidaxomicintreated patient.
The mean of the Shannon index of bacterial α diversity in stool samples was 3·39 (SD 0·93) at day 0 and 4·47 (0·73) at day 55 for 13 extended-pulsed fidaxomicin-treated patients, and 3·49 (1·23) at day 0 and 3·20 (1·24) at day 55 for nine vancomycintreated patients. The distribution of shift in Shannon index indicated that bacterial α diversity increased to a higher extent in extended-pulsed fidaxomicin-treated patients than in vancomycin-treated patients (median shift 0·83, IQR 0·51 to 1·68 vs -0·37, -0·80 to 0·79; figure 3 ) over the course of the study treatment and follow-up period. Presence of C difficile and microbial pathogens other than C difficile was analysed by a central laboratory in 332 samples taken at screening using a PCR-based multiplex test. Of these samples, 88% (292 of 332) were positive for C difficile and 23% (76 of 332) were positive for a gastrointestinal pathogen other than C difficile, of which enteropathogenic Escherichia coli was the most commonly identified (29 [9%] of 332; appendix).
Plasma pharmacokinetic analysis revealed low concentrations of fidaxomicin from days 5 to 25 or 26 (sampling depended on timing of extended-pulsed fidaxomicin dosing), in the range 3·75-175 ng/mL at 1-5 h after dosing. Median plasma fidaxomicin concentrations decreased in line with the change in dosing scheme. There was no accumulation of fidaxomicin in plasma over the extended dosing period.
Overall, the safety profile of extended-pulsed fidaxomicin seemed similar to that of the vancomycin regimen (table 4) . 87 (48%) of 181 adverse events in the extended-pulsed fidaxomicin group and 91 (50%) of 176 in the vancomycin group were classified as mild. Serious adverse events occurred in 68 (38%) extended-pulsed fidaxomicin-treated patients and 78 (43%) vancomycintreated patients. Three (2%) patients receiving extendedpulsed fidaxomicin and six (3%) patients receiving vancomycin had drug-related serious adverse events. The drug-related serious adverse events in the extendedpulsed fidaxomicin arm were one event (1%) each of pruritus, bile duct stone, and drug hypersensitivity; the latter two adverse events led to permanent discontinuation of study drug. The drug-related serious adverse events in the vancomycin arm were one event each of cardiac failure, ileus (leading to permanent discontinuation of study drug), treatment failure, Clostridium spp infection, Klebsiella spp infection, sepsis, somnolence, and eczema. 65 (18%) deaths occurred during the study, with 29 (16%) in the extended-pulsed fidaxomicin arm and 36 (20%) in the vancomycin arm (appendix). Only one death was related to study drug (as assessed by the investigator)-a 73-year-old woman in the vancomycin arm who died of sepsis and heart failure on day 12 (appendix). Data are n (%) unless otherwise indicated. Number of patients analysed is presented in square brackets if data are missing. OR=odds ratio. *Difference between the rates (extended-pulsed fidaxomicin and vancomycin) and the associated 95% CI around the difference, day 12 −1·9% (−10·0 to 6·2), p=0·721 and 2 days after end of treatment −4·2% (−12·5 to 4·1), p=0·399. †Patients were censored at day 10 for vancomycin (240 h after start of treatment) and at day 25 for extended-pulsed fidaxomicin (600 h after start of treatment). ‡147 patients were not included in the analysis as they had no unformed bowel movement records provided up to day 13. §For the vancomycin arm, unformed bowel movement records were collected only up to day 12 (plus or minus 2 days). ¶Treatment difference 39·1 (95% CI 13·2-64·9). ||Treatment difference 6·6 (95% CI -4·0 to 17·2). **Pathogens detected by multiplex PCR testing of faecal samples at screening in the safety analysis set, at treatment failure, Clostridium difficile recurrence, or unscheduled event. Other pathogens included non-C difficile bacterial, parasitic, and viral enteric pathogens, identified according to established methods (appendix). Data are n (%) unless otherwise indicated. Number of patients analysed is presented in square brackets if data are missing. OR=odds ratio. *Difference between the rates (extended-pulsed fidaxomicin and vancomycin) and the associated 95% CI around the difference, day 12 2·3% (−5·6 to 10·3), p=0·621 and at 2 days after end of treatment 6·3% (−0·9 to 13·6), p=0·131. †Patients were censored at day 10 (240 h after start of treatment) for vancomycin and day 25 (600 h after start of treatment) for extended-pulsed fidaxomicin. ‡99 patients were not included in the analysis as they had no unformed bowel movement records provided up to day 13. §For the vancomycin arm, unformed bowel movement records were collected only up to day 12 (plus or minus 2 days). ¶Treatment difference 19·1 (8·7-29·4; p=0·0011). 
Discussion
In this multicentre, randomised C difficile infection study testing the concept of pulsed dosing as a microbiotasparing strategy, extended-pulsed fidaxomicin was superior to standard-dose vancomycin for the primary endpoint of sustained clinical cure of C difficile infection in patients aged 60 years and older. Crucial to the achievement of sustained clinical cure, the recurrence rate observed in the present study was lower in the extended-pulsed fidaxomicin arm than in the vancomycin arm at every visit up to day 90. The recurrence rate at day 90 in the extended-pulsed fidaxomicin arm (6%) was lower than was reported in previous randomised, controlled studies of standard regimens of fidaxomicin, vancomycin, and metronidazole. 3, 12, 13 A recurrence rate of 8-26%, depending on previous recurrence, was observed in a real-world study of fidaxomicin. 16 Follow-up to day 90, as in our study, is unusual and gives added insight and, to our knowledge, such a long follow-up has only been reported in the registration study of the monoclonal antibody bezlotoxumab. 17 Although the sustained clinical cure of C difficile infection achieved at 30 days after the end of extendedpulsed fidaxomicin treatment in our study (70%) was similar to that achieved in phase 3 studies with a standard twice-daily, 10-day course of fidaxomicin (214 [75%] of 287 patients; 13 221 [88%] of 252 patients 12 ), the results of these previous studies are not directly comparable to ours because of differences in study design and outcome criteria. Patients in EXTEND were older than were those in previous studies (mean 75·1 years [SD 8·7] compared with 61·6 years [16·9] 13 and 63·4 years [18·1] 12 ) to stress test the regimen, and the recurrence rate was substantially lower at 90 days with extended-pulsed fidaxomicin in EXTEND (6%) than it was at 40 days with standard fidaxomicin in previous phase 3 studies (39 [15%] of 253 patients; 13 28 [13%] of 221 patients 12 ) .
Patients older than 65 years have a greater relative risk of C difficile infection recurrence than do younger patients, and patients aged at least 75 years have a higher odds ratio for mortality before 30 days. 18 The reduction in recurrence rates observed with extended-pulsed fidaxomicin compared with previous studies suggests potential health-care benefits beyond the studied clinical endpoints. In the extended-pulsed fidaxomicin regimen, the same number of fidaxomicin tablets is administered as in the standard licensed regimen, but enhanced outcomes are seen compared with vancomycin, potentially resulting in a cost-effectiveness benefit. Additionally, as C difficile infection recurrence has high cost implications, avoidance of recurrence is considered economically important, particularly in high-risk patients. 19 For every seven patients treated with fidaxomicin, an estimated one hospital readmission for C difficile infection is prevented compared with patients treated with vancomycin. 20 In our study of an older patient population, the number needed to treat with extended-pulsed fidaxomicin is estimated at 6·6, derived from the absolute difference in recurrence rate with vancomycin at a similar timepoint of 40 days. Recurrence rates observed in the vancomycin arm were lower than those previously reported in the vancomycin arm of fidaxomicin phase 3 registration trials. 12, 13 Epidemiological changes, differences in antimicrobial stewardship and infection control, and differences in the characteristics or treatment of the patient population might have contributed to this reduction in recurrence with vancomycin. However, reported recurrence rates with Data are presented as n (%). *Defined as adverse events causing inability to perform daily activities. †Possibly or probably related to study drug, as assessed by the investigator, or records where relationship was missing. ‡Defined as adverse events resulting in death, or considered to be life-threatening, requiring hospitalisation, or resulting in persistent or substantial disability or incapacity, congenital anomaly, or other medically important events. §A woman aged 79 years had drug hypersensitivity (rash and bronchospasm) of moderate intensity on treatment day 3. The event was considered serious and probably related to treatment. Dechallenge with enhanced-pulsed fidaxomicin was positive. Enhanced-pulsed fidaxomicin was permanently withdrawn. The event resolved on day 7 after treatment for hypersensitivity. This side-effect is noted on the fidaxomicin label. 15 ¶Reported in at least 5% of patients in any treatment group. ||All treatment-emergent adverse advents recorded as Clostridium spp infection were Clostridium difficile infection. vancomycin in this study align with reported recurrence rates in a retrospective cohort study. 21 In phase 3 studies, no significant difference in efficacy was observed between fidaxomicin and vancomycin in patients with PCR ribotype 027 infections. 13 In our study, extended-pulsed fidaxomicin was associated with an increased rate of sustained clinical cure compared with vancomycin at 30 days after end of treatment in this patient subgroup. However, as with previous studies, EXTEND was not sufficiently powered to permit strong conclusions on differences in efficacy in patients with PCR ribotype 027 infections.
Vancomycin therapy is detrimental to the gut microbiota, with depletion of many bacterial types (operational taxonomic units), particularly from the Bacteroidetes phylum, and the proportion of several organisms associated with human infection, such as Klebsiella spp, Escherichia spp, vancomycin-resistant enterococci, and Candida spp, is increased after treatment. 11, 22 Analysis of the Shannon index of α diversity indicated that extended-pulsed fidaxomicin enhanced microbiota recovery over our study period to a significantly higher degree than did vancomycin, providing support for extended-pulsed fidaxomicin as a microbiota-sparing treatment strategy. This increased microbial diversity in patients treated with extendedpulsed fidaxomicin will be of interest for future studies, and suggests a possible mechanistic basis for the reduced recurrence rates observed in this study.
More deaths occurred in the vancomycin arm of our study, but of greater interest is the higher number of deaths among vancomycin recipients after day 27. Recurrence has been found to be associated with increased mortality by day 90 after hospital discharge. 23 A limitation of our study is the absence of standard fidaxomicin or extended-pulsed vancomycin arms. Although additional treatment arms offer improved certainty and depth of information, they also represent a major cost driver in clinical trials, which can limit their feasibility. Furthermore, vancomycin is considered the standard of care for C difficile infection and was therefore the most appropriate comparator arm. 3 In the present setting, data from previous studies provide sufficient insight to justify omission of additional treatment arms. In-vitro data from a gut model of C difficile infection primed with faeces from an older population (aged >60 years) do not suggest that incorporating standard and extended-pulsed regimens of fidaxomicin would differ in terms of efficacy in resolving C difficile infection, 14 and our observed similarity in clinical response rates at day 12 between extended-pulsed fidaxomicin and vancomycin supports this hypothesis. This observation, combined with data from randomised clinical studies showing a recurrence rate of 15·4% or lower for the standard fidaxomicin regimen, 12, 13 suggests outcomes that are at least as good for extended-pulsed fidaxomicin compared with standard fidaxomicin; however, a future indirect treatment comparison of these regimens could be of interest to further understand their relative effectiveness. Retrospective observational data suggest potential efficacy of extended-pulsed vancomycin for recurrent C difficile infection. 24 However, laboratory studies have shown the disruptive effect of vancomycin on gut microbiota, 25 and such an extended regimen could further exacerbate post-treatment gut microbiota dysbiosis.
This study's definition of C difficile infection recurrence-based on worsening symptoms-reflected clinical practice, but could be perceived as yielding a low threshold for examining recurrence. Nevertheless, diagnosis required the investigator to treat for recurrence based on their clinical judgment. The absence of blinding and insufficient racial diversity in the study population might also be considered limitations of this study. Furthermore, the study does not provide information on the use of extended-pulsed fidaxomicin in patients younger than 60 years, or in those with at least three C difficile infection recurrences.
Our study has many strengths, including, to our knowledge, the first demonstration in a randomised clinical trial setting of a C difficile infection recurrence rate less than 7% by optimising the delivery of an already available antibiotic. This hypothesis-driven study uses our understanding of C difficile infection pathogenesis and the method of action of fidaxomicin to enhance the dosing regimen and improve outcomes in a high-risk patient population. 90-day follow-up provided an extensive period over which reinfection or recurrence could be studied and gave important new data on C difficile infection recurrence. Incorporation of a microbiota substudy analysis also provided evidence to explain and validate observed clinical outcomes.
EXTEND is an uncommon positive superiority antibiotic trial, showing an improvement in sustained clinical cure of C difficile infection with extended-pulsed fidaxomicin and a significant reduction in recurrence rates compared with vancomycin treatment, even up to day 90, with simultaneous enhanced microbiota recovery. Since the extended-pulsed regimen of fidaxomicin administers the same number of tablets as the standard regimen, the observed benefits are derived with no increase in treatment costs and with a similar positive safety profile to that of standard-regimen vancomycin and fidaxomicin. Furthermore, the C difficile recurrence rate of 4% at 30 days after end of treatment is, to date, the lowest observed in a randomised clinical trial.
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